Charles Schwab’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Charles Schwab’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$660K	Buy	214,915 +6,650	+3%	+$20.4K	﹤0.01%	3020
2025 Q4	$741K	Buy	208,265 +20,731	+11%	+$76.9K	﹤0.01%	3022
2025 Q3	$654K	Buy	187,534 +40,000	+27%	+$137K	﹤0.01%	3083
2025 Q2	$302K	Buy	+147,534	New	+$369K	﹤0.01%	3306
2023 Q2	–	Sell	-87,594	Closed	-$59.4K	–	3680
2023 Q1	$59.4K	Hold	87,594	–	–	﹤0.01%	3323
2022 Q4	$145K	Hold	87,594	–	–	﹤0.01%	3229
2022 Q3	$406K	Buy	87,594 +46,333	+112%	+$272K	﹤0.01%	3061
2022 Q2	$209K	Buy	+41,261	New	+$300K	﹤0.01%	3237

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab's STLN Position: Q1 2026 in Review

Charles Schwab increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 3.2% in Q1 2026, buying an estimated $20.4K and bringing the position to 214,915 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #3020.

Charles Schwab first reported a position in STLN in Q2 2022 and has held it in 8 quarters since. The position peaked at $741K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

Charles Schwab held 214,915 shares of Starling Oncology Institute, Inc. Common Stock worth $660K as of Q1 2026.
Charles Schwab bought 6,650 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $20.4K.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3020 holding.
Charles Schwab first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2022 and has held it in 8 quarters since.
Charles Schwab's Starling Oncology Institute, Inc. Common Stock position peaked at $741K in Q4 2025.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.